BRIEF-AstraZeneca Plc Says Nirsevimab PhII/III Trial Confirms Safety Profile

AstraZeneca PLC: * ASTRAZENECA PLC - NIRSEVIMAB PHII/III TRIAL CONFIRMS SAFETY PROFILE

* ASTRAZENECA - NIRSEVIMAB MEDLEY PHASE II/III TRIAL DEMONSTRATED FAVOURABLE SAFETY AND TOLERABILITY PROFILE IN INFANTS AT HIGH RISK OF RSV * ASTRAZENECA - NIRSEVIMAB IS BEING DEVELOPED AS A PASSIVE IMMUNISATION AGAINST RSV FOR ALL INFANTS

* ASTRAZENECA - TRIAL ASSESSED SAFETY OF NIRSEVIMAB IN INFANTS WITH CHRONIC LUNG DISEASE (CLD), CONGENITAL HEART DISEASE (CHD) AND/OR PREMATURITY * ASTRAZENECA - OCCURRENCE OF TREATMENT EMERGENT ADVERSE EVENTS OR TREATMENT EMERGENT SERIOUS ADVERSE EVENTS (TESAES) WERE SIMILAR BETWEEN GROUPS. Source text for Eikon: Further company coverage:

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)